Equity (Details) $ / shares in Units, dose in Millions						1 Months Ended		3 Months Ended	4 Months Ended	9 Months Ended
	Apr. 27, 2021 USD ($)	Apr. 23, 2021 $ / shares shares	Mar. 01, 2021 dose $ / shares shares	Feb. 10, 2021 USD ($)	Feb. 07, 2021 $ / shares shares	Jun. 30, 2020 USD ($) shares	Apr. 30, 2020 USD ($) shares	Sep. 30, 2020 USD ($) shares	Aug. 31, 2020 at-the-marketOffering	Sep. 30, 2021 USD ($) dose $ / shares shares	Sep. 30, 2020 USD ($) shares	Apr. 30, 2021 shares	Apr. 29, 2021 shares	Dec. 31, 2020 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares										$ 0.01				$ 0.01
Common stock, shares authorized (in shares) | shares										295,000,000		295,000,000	200,000,000	200,000,000
Number of at-the-market offerings | at-the-marketOffering									3
Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding										$ 5,000,000
Series B Warrants | Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input										0.15
COVAXIN Preferred Stock Purchase Agreement | Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Agreement to sell, number of shares issued in transaction (in shares) | shares			100,000
Convertible preferred stock, par value (in USD per share) | $ / shares			$ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares			$ 109.60
Convertible preferred stock, shares issued upon conversion (in shares) | shares			10
Supply agreement, number of doses | dose			10.0							10.0
Registered Direct Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares		10,000,000			3,000,000
Price per share (in USD per share) | $ / shares		$ 10.00			$ 7.65
Proceeds from sale of stock	$ 93,400,000			$ 21,200,000
Commissions, fees and expenses	$ 6,600,000			$ 1,700,000
ATMs
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares								27,000,000		1,000,000	86,200,000
Proceeds from sale of stock								$ 10,100,000		$ 4,800,000	$ 25,600,000
Commissions, fees and expenses								$ 400,000		$ 100,000	$ 1,100,000
Subscription Agreements
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares						1,300,000	1,000
Proceeds from sale of stock							$ 395
Accredited investors agreement to cancel outstanding obligation						$ 300,000
Accredited investors agreement to cancel additional portion owed representing a discount						$ 200,000